LENZ Therapeutics, Inc. (LENZ)
2.965
-0.38
(-11.23%)
USD |
NASDAQ |
Nov 20, 16:00
2.96
0.00 (0.00%)
After-Hours: 20:00
LENZ Therapeutics Research and Development Expense (TTM) : 0.00 for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.00 |
| June 30, 2026 | 3.791M |
| March 31, 2026 | 12.85M |
| December 31, 2025 | 18.67M |
| September 30, 2025 | 24.54M |
| June 30, 2025 | 27.20M |
| March 31, 2025 | 25.08M |
| December 31, 2024 | 29.80M |
| September 30, 2024 | 43.47M |
| June 30, 2024 | 54.02M |
| March 31, 2024 | 59.72M |
| December 31, 2023 | 59.50M |
| Date | Value |
|---|---|
| September 30, 2023 | 56.21M |
| June 30, 2023 | 55.34M |
| March 31, 2023 | 60.48M |
| December 31, 2022 | 68.40M |
| September 30, 2022 | 63.36M |
| June 30, 2022 | 55.91M |
| March 31, 2022 | 50.80M |
| December 31, 2021 | 37.93M |
| September 30, 2021 | 33.12M |
| June 30, 2021 | 26.74M |
| March 31, 2021 | 14.50M |
| December 31, 2020 | 9.123M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| EyePoint, Inc. | 296.65M |
| Ligand Pharmaceuticals, Inc. | 23.09M |
| Bristol Myers Squibb Co. | 9.479B |
| Context Therapeutics, Inc. | 37.10M |
| Neumora Therapeutics, Inc. | 135.16M |